Heart researchers unpack neutral findings from ZEUS, an anti-inflammatory clinical trial

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Like cholesterol, inflammation causally contributes to the risk of cardiovascular disease, but findings from the clinical trial ZEUS indicate that the road to targeting inflammation may be less straightforward than once thought. ZEUS, a global phase 3 clinical trial led by Mass General Brigham researcher Paul Ridker, M.D., tested a drug that targets interleukin-6 (IL-6), a downstream inflammatory…

Read original article on Medical Xpress - latest medical and health news stories →

Related news